NCCN 2016

 
 
 

 

MF assessment and treatment an ‘evolution’ from the past

Erilyn Riley Read Article
Published: 10/11/16

mesa-ruben-ASCO15_Zach_Boyden-Holmes_230.jpg
Ruben Mesa, MD
© ASCO/Zach Boyden-Holmes

The 11th NCCN Congress: Hematologic Malignancies coincided with the release of the inaugural edition of the NCCN treatment guideline on myeloproliferative neoplasms (MPNs), and Ruben A. Mesa, MD, took the opportunity to discuss the framework of the document and the evolving management of MPNs. Dr Mesa, of the Mayo Clinic Cancer Center in Arizona, is the chair of the MPN guideline committee. [Read Article]

Supportive care isn’t palliative care, speaker says

Erilyn Riley Read Article
Published: 10/08/16

nurse_explaining_info_in_pamphlet_NCI_230.jpg
Nurse converses with patient
Photo courtesy of NCI

Two presentations at the NCCN 11th Annual Congress: Hematologic Malignancies addressed the importance of supportive care in the treatment of patients with T-cell lymphomas and multiple myeloma. Erin Kopp, ACNP-BC, of City of Hope Comprehensive Cancer Center in Duarte, California, reminded the audience that supportive care is not palliative care. Supportive care “complements critical care so that the patient doesn’t have to stop treatment,” she said. [Read Article]

Speaker outlines importance of cell of origin in DLBCL

Erilyn Riley Read Article
Published: 10/07/16

Zelenetz_NCCN2016.jpg
Andrew Zelenetz, MD, PhD

The importance of cell of origin in choosing a treatment for diffuse large B-cell lymphoma (DLBCL) is a topic “that has been kicking around for 16 years,” according to a speaker at the NCCN 11th Annual Congress: Hematologic Malignancies. Cell of origin was first described in the year 2000 as a distinguishing factor in large-cell lymphoma, said the speaker, Andrew Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York. [Read Article]

‘Practice-changing’ treatments emerging in AML

Erilyn Riley Read Article
Published: 10/06/16

AML_in_bone_marrow_240.jpg
AML cells in bone marrow

We are “finally” making progress in the treatment of acute myeloid leukemia (AML), according to a speaker at the NCCN 11th Annual Congress: Hematologic Malignancies. Jessica K. Altman, MD, said a number of developments have resulted in improved AML treatment, including a better understanding of biology and prognostic assessment, continued advances in transplant, and updating standard treatments and incorporating novel . . . [Read Article]

Doc offers advice on choosing a frontline TKI

Erilyn Riley Read Article
Published: 10/06/16

imatinib_tablet_Credit_D_Meyer_230.jpg
Imatinib (Gleevec) tablet
Photo by D. Meyer

Evaluating treatment goals is essential when choosing which tyrosine kinase inhibitor (TKI) to prescribe a patient with newly diagnosed chronic myeloid leukemia (CML), according to a speaker at the NCCN 11th Annual Congress: Hematologic Malignancies. “Deciding what TKI to start people on really depends on what your goals are for that patient,” said the speaker, Jerald Radich, MD, of the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}